Morgan Stanley Maintains Equal-Weight on 2seventy bio, Lowers Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison maintains an Equal-Weight rating on 2seventy bio (NASDAQ:TSVT) but lowers the price target from $7 to $6.

July 29, 2024 | 4:30 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Morgan Stanley analyst Matthew Harrison maintains an Equal-Weight rating on 2seventy bio (NASDAQ:TSVT) but lowers the price target from $7 to $6.
The lowered price target from $7 to $6 by a major financial institution like Morgan Stanley is likely to have a negative short-term impact on TSVT's stock price. The Equal-Weight rating suggests a neutral stance, but the reduced price target indicates lowered expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100